Brown JE - Search Results

1

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.

Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ. Lipton A, et al. Among authors: brown je. Clin Cancer Res. 2016 Dec 1;22(23):5713-5721. doi: 10.1158/1078-0432.CCR-15-3086. Epub 2016 May 2. Clin Cancer Res. 2016. PMID: 27140926 Free article. Clinical Trial.

2

Bone resorption predicts for skeletal complications in metastatic bone disease.

Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Brown JE, et al. Br J Cancer. 2003 Dec 1;89(11):2031-7. doi: 10.1038/sj.bjc.6601437. Br J Cancer. 2003. PMID: 14647134 Free PMC article.

3

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Brown JE, et al. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69. doi: 10.1093/jnci/dji002. J Natl Cancer Inst. 2005. PMID: 15632381

4

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Coleman RE, et al. Among authors: brown je. J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983391

5

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.

Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I. Santini D, et al. Among authors: brown je. Oncol Rep. 2006 May;15(5):1351-7. Oncol Rep. 2006. PMID: 16596210

6

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Cook RJ, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269. Clin Cancer Res. 2006. PMID: 16740758 Clinical Trial.

7

Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.

Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ, Coleman RE. Brown JE, et al. Clin Cancer Res. 2006 Nov 1;12(21):6480-6. doi: 10.1158/1078-0432.CCR-06-1382. Clin Cancer Res. 2006. PMID: 17085662

8

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

9

Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Brown JE, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5406-10. doi: 10.1158/1078-0432.CCR-07-0247. Clin Cancer Res. 2007. PMID: 17875770 Clinical Trial.

10

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Hirsh V, et al. Among authors: brown je. J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e. J Thorac Oncol. 2008. PMID: 18317064 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

765 results

Search Page

Filters